article thumbnail

Moderna leads the development of mRNA vaccines in infectious diseases

Pharmaceutical Technology

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

article thumbnail

BioNTech targets infectious diseases for vaccine development

Pharmaceutical Technology

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evaxion Biotech to develop new vaccines for cancer

Pharmaceutical Technology

Evaxion Biotech has announced plans to develop customised cancer vaccines by targeting a category of AI-discovered tumour antigens.

article thumbnail

US launches $5bn effort for new Covid-19 vaccines development

Pharmaceutical Technology

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

article thumbnail

Oragenics secures CQDM funding for Covid-19 vaccine antigen development

Pharmaceutical Technology

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

article thumbnail

LimmaTech secures funding for vaccine technology development

Pharmaceutical Technology

LimmaTech announced the closing of a second round of its Series A financing, securing $3m from Tenmile for vaccine technology development.

article thumbnail

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.